Science Behind

Xlear Products

Xlear Inc. centers on proactive health—staying healthy through transformational hygiene. Xlear xylitol-based products support that goal.

From the time that Ignaz Semmelweiss first wrote about the need for physicians to wash their hands between patients and the time that it became the standard of care (or mandated because it wasn’t being done) was 150 years. Semmelweiss was ridiculed, laughed at, and discredited, but history proved him correct. Washing our hands and our nose are simple hygienic ways that we can stop the spread of bacteria and viruses.

Nasal hygiene is more important to our health than washing our hands. Washing our hands helps stop the spread of infections, but how often do you really get sick through your hands? Practically zero. You get sick when you touch your hands to your face, your nose, your eyes where bacteria and viruses can easily enter the body.

Wouldn’t it make more sense to wash our nose with something that blocks viral and bacterial adhesion?

The nose is where bacteria and viruses enter the body.  Nearly 75% of the visits to primary care physicians in the U.S. are related to upper respiratory issues. We can bring that number down significantly if we start washing our nose.

Let’s transform our hygiene and make it more effective. Wash your nose with Xlear.

Need more convincing? Read the studies below that support cleaning your nose with Xlear.

Anti-Adherence of Bacteria – 1998

This study found that xylitol blocked adhesion of bacteria to epithelial cells, showing that xylitol inhibits bacteria from sticking to tissue, which allows the body to wash them away.

Kontiokari, T., Uhari, M., & Koskela, M. (1998). Antiadhesive effects of xylitol on otopathogenic bacteria. The Journal of Antimicrobial Chemotherapy, 41(5), 563–565.

Read the Study

Xylitol Nasal Irrigation in the Management of Chronic Rhinosinusitis – 2011

In this pilot study, researchers wanted to find out if irrigating the sinuses with a water-xylitol solution would improve symptoms of people suffering from chronic rhinosinusitis. They concluded, “Xylitol irrigations result in greater improvement of symptoms of chronic rhinosinusitis as compared to saline irrigation.”
Weissman, J. D., et al. (2011). Xylitol nasal irrigation in the management of chronic rhinosinusitis: a pilot study. The Laryngoscope, 121(11), 2468–2472.
Read the Study

Airway Study – 2015

In a 2015 presentation, Dr. Nsouli shared his findings of a study which showed that a nasal spray with xylitol increased peak airflow 36% more than saline alone and measurably increased participants’ quality of life.

Nsouli, T. M.; et al., (2015) ORAL ABSTRACT #46.

Improved Nasal Volume Utilizing Hyperosmotic Saline Xylitol Mixture (Effective Alternative or Adjunct to Decongestants and Antihistamines) – 2019

In this article Drs. Olmos and Baba discuss their findings which showed that 3 minutes after spraying participants’ noses with a saline and xylitol spray, they experienced a  20% improvement in airway volume.
Olmos, S., Baba, J., (2019.). Improved Nasal Volume Utilizing Hyperosmotic Saline Xylitol Mixture (Effective Alternative or Adjunct to Decongestants and Antihistamines). EC Pulmonology and Respiratory Medicine 8.5, 444-452.
Read the Study

High Viral Load in the Nose – Mar. 2020

In this correspondence, researchers shared their research which showed that the nose has the highest viral load of SARS-CoV-2 than elsewhere in the body when infected with the virus.

Zou, L., et al., (2020). SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. The New England Journal of Medicine, 382(12), 1177–1179.
Read the Correspondence

Mapping How SARS-CoV-2 Infects the Body – May, 2020

In this study done at UNC Chapel Hill, researchers found that the SARS-CoV-2 virus first infects the body through the nose, establishes itself there, and then progresses into the airway and lungs.

Hou, Y. J., et al., (2020). SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell, 182(2), 429-446.e14.
Read the Study

The Three Stages of SARS-CoV-2 Infection – Jul. 2020

The paper’s authors show that like other illnesses which affect the lungs, the SARS-CoV-2 virus has three stages of infection, and if left unchecked, it could cause irreversible damage to lungs. They argue medical professionals must give greater attention and treatment in the earlier stages of infection.
Sanchez-Gonzalez, M. A., et al., (2020). A Pathophysiological Perspective on COVID-19’s Lethal Complication: From Viremia to Hypersensitivity Pneumonitis-like Immune Dysregulation. Infection & Chemotherapy, 52(3), 335–344.
Read the Study

Benefits and Safety of Nasal Saline Irrigations in a Pandemic—Washing SARS-CoV-2 Away – Jul. 2020

In this paper, researchers discuss how cleaning the sinuses with a simple saline could be useful during the pandemic. They conclude saying that adding an anti-viral or virucidal agents to the saline could be beneficial against SARS-CoV-2.
Farrell NF, et al. (2020). Benefits and Safety of Nasal Saline Irrigations in a Pandemic—Washing COVID-19 Away. JAMA Otolaryngol Head Neck Surg., 146(9):787–788.
Read the Study

Anti-Adherence of SARS-CoV-2 Virus – Aug. 2020

In a study looking at Iota-carrageenan’s effect on SARS-CoV-2, researchers found that xylitol also had an anti-adherence effect on the virus.
Vega, J. C., et al., (2020). Iota carrageenan and xylitol inhibit SARS-CoV-2 in Vero cell culture. BioRxiv.
Read the Study

Using Nasal Sprays to Combat SARS-CoV-2 – Sept. 2020

Researchers concluded that using a nasal spray that deactivates the SARS-CoV-2 virus in the nose, “may not only prevent person-to-person spread of SARS-CoV-2, but may also diminish the severity of disease in patients by limiting spread and decreasing viral load delivered to the lungs.”
Frank, S., et al., (2020). In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2. JAMA Otolaryngology– Head & Neck Surgery.
Read the Study

Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution with SARS-CoV-2: Case Series – Nov. 2020

In this case study, participants experienced a reduction of symptoms related to SARS-CoV-2 infection and received a negative test 50% faster than the average time of negativization.
Go, C. C., et al., (2020). Potential Role of Xylitol Plus Grapefruit Seed Extract Nasal Spray Solution in COVID-19: Case Series. Cureus, 12(11), e11315.
Read the Study

Xylitol’s Method of Action against SARS-CoV-2 – Nov. 2020

Antony Cheudjeu found that xylitol blocks receptor cites of the SARS-CoV-2 virus which inhibits it from attaching to the cell wall of its host.
Cheudjeu, A. (2020). Correlation of D-xylose with severity and morbidity-related factors of COVID-19 and possible therapeutic use of D-xylose and antibiotics for COVID-19. Life Sciences, 260, 118335.
Read the Study

Deactivation of SARS-CoV-2 with Xlear Nasal Spray – Nov. 2020

In this paper, researchers look at two studies performed at Utah State University (2020) and University of Geneva (2020) which showed that Xlear Nasal Spray destroyed 99.99% of the SARS-CoV-2 virus.
Ferrer, G., et al., (2020). A Nasal Spray Solution of Grapefruit Seed Extract plus Xylitol Displays Virucidal Activity Against SARS-Cov-2 In Vitro. BioRxiv.
Read the Study
Microscope images SARS-CoV-2 and cells

Further Evidence of Xylitol’s Effectiveness Against SARS-CoV-2, H1N1, and Other Viruses – Jan. 2021

In this study researchers used an electron microscope to take pictures of xylitol’s and grapefruit seed extract’s (GSE) interaction with the SARS-CoV-2 virus. They concluded, “Combination therapy with GSE and xylitol may prevent spread of viral respiratory infections not just for SAR-CoV-2 but also for future H1N1 or other viral epidemics. GSE significantly reduces the viral load while xylitol prevents the virus attachment to the core protein on the cell wall.”
Cannon, M. L., et alk., (2020). In Vitro Analysis of the Anti-viral Potential of nasal spray constituents against SARS-CoV-2. BioRxiv.
Read the Study

PAASE Bulletin 18: Use of Povidone-Iodine to reduce transmission of SARS-CoV2 virus – Jan. 2021

The Philippines has recognized the benefit of using anti-viral and virucidal nasal sprays as an adjunct therapy to mitigate the spread of the SARS-CoV-2 virus. Government officials now officially recommend the usage of these sprays to combat the virus.
Read the Announcement

Comprehensive Literature Review of Intranasal Therapy Against SARS-CoV-2 – Jan. 2021

In this review, researchers looked at all the studies talking about intranasal therapy in fighting against SARS-CoV-2. They concluded, “Based on the literature review, it is encouraging to note that studies reviewed note that using nasal spray with antiviral properties has promising efficiency and safety in the treatment and prophylaxis against SARS-CoV-2…We propose that intranasal administration of antiviral and virucidal therapies decrease the viral activity in the nasal pathway, thus preventing disease transmission, expedite recovery of patients, decrease severity of symptoms, reduce hospitalization, and mortality.”
Go, Camille Celeste, et al., (2021). Intranasal therapy and COVID-19: A comprehensive literature review. Journal of Allergy and Infectious Diseases. 2(1):9-16
Read the Review

Medical Disclaimer per FTC Guidelines

While there may be information on the Xlear website relating to certain conditions, including COVID, cold, flu and similar condition, should a medical condition exist, promptly see your own physician or health provider. Xlear does not offer medical diagnosis or treatment advice. Xlear makes no claims that it can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials, including COVID, cold, flu and similar condition. The information, including any scientific or clinical research, is made available for educational purposes only. This information helps people make informed decisions about potential treatment options for the various conditions referenced in the information. Xlear therefore makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments available or that may be made available. However, research is not considered conclusive. Always consult your healthcare provider with any questions.
If you take prescription medications for any of these conditions or other conditions, including sinus and related conditions such as congestion, you should consult with your physician before discontinuing use of such medications as Xlear is not intended to replace or supplement any prescription medications.
Statements with regards to Xlear products are the opinions of the individuals making them and are not necessarily the same as those of Xlear Inc.

Xlear Inc. Statment on FTC Guidelines

Recently Xlear has removed a number of scientific studies and posted disclaimers on our website and social media. We have done this at the insistence of the Federal Trade Commission. We believe the FTC has no authority to stop us from giving you accurate scientific information. Moreover, the FTC lacks the scientific/medical expertise to evaluate such data. However, we are trying to work with the FTC to fix this.

We believe that you have a right to accurate and actionable scientific studies and data. We believe that accurate scientific data and studies are vital in helping individuals make smart and informed health decisions for themselves and their families.